Indian Journal of Ophthalmology

: 2019  |  Volume : 67  |  Issue : 7  |  Page : 1171--1173

Multimodal imaging in non-paraneoplastic autoimmune retinopathy

David Kasongole1, Vishal Raval1, Prithvi Mruthyunjaya2, Raja Narayanan1,  
1 L.V. Prasad Eye Institute, Hyderabad, India
2 Byers Eye Institute, Stanford University School of Medicine, California, USA

Correspondence Address:
Dr. Raja Narayanan
M.S., L.V. Prasad Eye Institute, Banjara Hills, Hyderabad, Telangana - 500 034

How to cite this article:
Kasongole D, Raval V, Mruthyunjaya P, Narayanan R. Multimodal imaging in non-paraneoplastic autoimmune retinopathy.Indian J Ophthalmol 2019;67:1171-1173

How to cite this URL:
Kasongole D, Raval V, Mruthyunjaya P, Narayanan R. Multimodal imaging in non-paraneoplastic autoimmune retinopathy. Indian J Ophthalmol [serial online] 2019 [cited 2019 Aug 21 ];67:1171-1173
Available from:

Full Text

Autoimmune retinopathy (AIR) is a rare inflammatory disease, which remains underdiagnosed due to lack of specific diagnostic criteria.[1] Most of the patients present with bilateral, sudden progressive loss of vision,[2] visual field defects, and scotomas. The diagnostic criteria for AIR include any history of autoimmune disease in the family, clinical symptoms of progressive loss of vision, presence of circulating autoantibodies against the retinal antigens, and alterations on full-field electroretinography (ERG).[3] AIR can be classified into paraneoplastic and non-paraneoplastic AIR (npAIR). Paraneoplastic AIR is further divided into cancer-associated retinopathy and melanoma-associated retinopathy, vitelliform maculopathy, and bilateral diffuse uveal melanocytic proliferation.[4] AIR presents with diagnostic and management challenge, and the treatment of this spectrum of disease remains unclear although a proposed modified Delphi system of essential and supportive diagnostic criteria has been recently proposed.[4] So far, there has been only one case of AIR reported from India.[5] We describe multimodal imaging in a patient of serologically confirmed npAIR.

A 44-year-old female presented with chief complaints of diminution of vision particularly at night, and glare. She gave a history of rapid loss of vision from 20/20 to 20/200 in both the eyes within 1 year. Fundus examination showed granular foveal pigmentation and subretinal yellow-white deposits in both eyes [Figure 1]a and [Figure 2]a. Fundus autofluorescence (FAF) showed marked hypoautoflorescence corresponding to the lesion with few areas of speckled hyperautofloresence at the fovea [Figure 1]b and [Figure 2]b. Red-free photography demonstrated hyperpigmented spots corresponding to the subretinal deposits at the posterior pole [Figure 1]c and [Figure 2]c. Swept-source optical coherence tomography (OCT) showed significant disorganization of the outer retinal layers and inner segment and outer segment junction with disruption of choriocapillaris layer, and dilation of vessels in Sattler's and Haller's layers [Figure 1]d and [Figure 2]d. Optical coherence tomography angiography (OCTA) showed signal void areas in choroidal vasculature in the central affected area [Figure 1]e,[Figure 1]f,[Figure 1]g,[Figure 1]h and [Figure 2]e,[Figure 2]f,[Figure 2]g,[Figure 2]h. ERG showed a reduction in amplitude spikes on both scotopic and photopic responses [Figure 3]a. The serology tests obtained on Western blot for all antiretinal antibodies against 23- (recoverin), 46- (enolase), 84-, 86-,96-, and 121-kDa proteins were positive. She was started on oral steroids. On her last visit at 12 months, the best-corrected visual acuity was 20/200; N24 with her fundus findings status quo and OCT, OCTA [Figure 4] and [Figure 5], and FAF showed no further degeneration of outer retinal layers and choriocapillaris. However, there was marked improvement in scotopic and photopic responses on her full-field ERG [Figure 3]b.{Figure 1}{Figure 2}{Figure 3}{Figure 4}{Figure 5}

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Forooghian F, Cao S, Cui J, Matsubara JA. The enigma of autoimmune retinopathy. Int Ophthalmol Clin 2016;55:81-91.
2Grange L, Dalal M, Nussenblatt RB, Sen HN. Autoimmune retinopathy. Am J Ophthalmol 2014;157:266-72.
3Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: A review and summary. Semin Immunopathol 2008;30:127-34.
4Fox AR, Gordon LK, Heckenlively JR, Davis JL, Goldstein DA, Lowder CY, et al. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol 2016;168:183-90.
5Abraham S, Sudharshan S, Bhende M, Ganesh SK, Gopal S. Antiretinal antibody-proven autoimmune retinopathy. Indian J Ophthalmol 2017;65:416-20.